Verification and evaluation of aldosteronism demographics in the Taiwan Primary Aldosteronism Investigation Group (TAIPAI Group)

Abstract

Objective: Current data on primary aldosteronism (PA) from Asian populations are scarce. This cohort study clarifies the attributes of patients with PA in a typical Chinese population.

Design: An observational cohort study.

Methods: The records of patients referred to the Hypertension Clinic from a multi-centre registration in Taiwan from January 1995 to December 2007 were reviewed. All patients with PA were classified into two subtypes: aldosterone-producing adenomas (APA) and idiopathic hyperaldosteronism (IHA); their characteristics were compared.

Results: Our cohort consisted of 346 patients with PA, 255 with APA and 91 with IHA. The initial hypokalaemia (59% in APA vs. 27.5% in IHA, p < 0.0001) and transtubular potassium gradient (TTKG) (6.30 ± 2.41 in APA vs. 4.91 ± 2.03 in IHA, p = 0.01) were higher in the APA group. Baseline plasma aldosterone concentration (PAC) was also significantly different between the two subgroups (49.96 ± 38.15 ng/dl in APA vs. 34.24 ± 21.47 in IHA, p < 0.0001).

Conclusions: In typical Chinese PA patients, the APA subgroup had a higher proportion of hypokalaemia with elevated TTKG and higher PAC as compared with the IHA subgroup. This largest Asian database also demonstrated major differences between the Caucasian and Chinese populations including female predilection, frequent hypokalaemia, and common paralytic myopathy.

Keywords

Aldosterone—renin ratio Chinese ethnicity demography primary aldosteronism

Get full access to this article

View all access options for this article.

References

Mulatero P. , Stowasser M. , Loh KC , et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045-1050.

Douma S. , Petidis K. , Doumas M. , et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet 2008; 371: 1921-1926.

Rossi GP , Bernini G. , Caliumi C. , et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006; 48: 2293-2300.

Milliez P. , Girerd X. , Plouin PF , Blacher J. , Safar ME and Mourad JJ Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248.

Conn JW Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955 ; 45: 3-17.

Loh KC , Koay ES , Khaw MC , Emmanuel SC and Young WF Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore . J Clin Endocrinol Metab 2000; 85: 2854-2859.

Omura M. , Sasano H. , Saito J. , Yamaguchi K. , Kakuta Y. and Nishikawa T. Clinical characteristics of aldosterone-producing microadenoma, macroadenoma, and idiopathic hyperaldosteronism in 93 patients with primary aldosteronism . Hypertens Res 2006; 29: 883-889.

Ma JT , Wang C. , Lam KS , et al. Fifty cases of primary hyperaldosteronism in Hong Kong Chinese with a high frequency of periodic paralysis. Evaluation of techniques for tumour localisation. Q J Med 1986; 61: 1021-1037.

Huang YY , Hsu BR and Tsai JS Paralytic myopathy - a leading clinical presentation for primary aldosteronism in Taiwan. J Clin Endocrinol Metab 1996; 81: 4038-4041.

10.

Wu VC , Chueh SC , Chang HW , et al. Bilateral aldosterone-producing adenomas: differentiation from bilateral adrenal hyperplasia. Q J Med 2008 ; 101: 13-22.

11.

Wu VC , Chang HW , Liu KL , et al. Primary aldosteronism: diagnostic accuracy of the losartan and captopril tests. Am J Hypertens 2009; 22: 821-827.

12.

Wu VC , Chueh SC , Chang HW , et al. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 2009; 54: 665-673.

13.

Charlson ME , Charlson RE , Peterson JC , Marinopoulos SS , Briggs WM and Hollenberg JP The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008; 61: 1234-1240.

14.

Chobanian AV , Bakris GL , Black HR , et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.

15.

Vidt DG Hypertensive crises: emergencies and urgencies. J Clin Hypertens (Greenwich) 2004; 6: 520-525.

16.

Martin JF , Higashiama E. , Garcia E. , Luizon MR and Cipullo JP Hypertensive crisis profile. Prevalence and clinical presentation. Arq Bras Cardiol 2004; 83: 131-6; 25-30.

17.

Yen RF , Wu VC , Liu KL , et al. 131I-6beta-iodomethyl-19-norcholesterol SPECT/CT for primary aldosteronism patients with inconclusive adrenal venous sampling and CT results . J Nucl Med 2009; 50: 1631-1637.

18.

Levey AS , Bosch JP , Lewis JB , Greene T. , Rogers N. and Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group . Ann Intern Med 1999; 130: 461-470.

19.

Levey AS , Coresh J. , Balk E. , et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.

20.

West ML , Marsden PA , Richardson RM , Zettle RM and Halperin ML New clinical approach to evaluate disorders of potassium excretion. Miner Electrolyte Metab 1986; 12: 234-238.

21.

Chang HW , Chu TS , Huang HY , et al. Down-regulation of D2 dopamine receptor and increased protein kinase Cmu phosphorylation in aldosterone-producing adenoma play roles in aldosterone overproduction. J Clin Endocrinol Metab 2007; 92: 1863-1870.

22.

Liao CH , Chueh SC , Lai MK , Hsiao PJ and Chen J. Laparoscopic adrenalectomy for potentially malignant adrenal tumors greater than 5 centimeters. J Clin Endocrinol Metab 2006; 91: 3080-3083.

23.

Aiba M. , Suzuki H. , Kageyama K. , et al. Spironolactone bodies in aldosteronomas and in the attached adrenals. Enzyme histochemical study of 19 cases of primary aldosteronism and a case of aldosteronism due to bilateral diffuse hyperplasia of the zona glomerulosa. Am J Pathol 1981; 103: 404-410.

24.

Omura M. , Sasano H. , Fujiwara T. , Yamaguchi K. and Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling . Metab Clin Exp 2002; 51: 350-355.

25.

Novitsky YW , Kercher KW , Rosen MJ , Cobb WS , Jyothinagaram S. and Heniford BT Clinical outcomes of laparoscopic adrenalectomy for lateralizing nodular hyperplasia. Surgery 2005; 138: 1009-1016; discussion 16-17.

26.

Rossi GP , Belfiore A. , Bernini G. , et al. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007; 50: 424-431.

27.

Schwartz GL and Turner ST Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 2005; 51: 386-394.

28.

Jonsson JR , Klemm SA , Tunny TJ , Stowasser M. and Gordon RD A new genetic test for familial hyperaldosteronism type I aids in the detection of curable hypertension. Biochem Biophys Res Commun 1995; 207: 565-571.

29.

Su FH , Cheng SH , Li CY , et al. Hepatitis B seroprevalence and anamnestic response amongst Taiwanese young adults with full vaccination in infancy, 20 years subsequent to national hepatitis B vaccination. Vaccine 2007; 25: 8085-8090.

30.

Walz MK , Gwosdz R. , Levin SL , et al. Retroperitoneoscopic adrenalectomy in Conn’s syndrome caused by adrenal adenomas or nodular hyperplasia. World J Surg 2008; 32: 847-853.

31.

Hiramatsu K. , Yamada T. , Yukimura Y. , et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients . Arch Intern Med 1981; 141: 1589-1593.

32.

Sartori M. , Calo LA , Mascagna V. , et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006; 19: 373-9; discussion 80.

33.

Mosso L. , Carvajal C. , Gonzalez A. , et al. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161-165.

34.

Sechi LA , Novello M. , Lapenna R. , et al. Long-term renal outcomes in patients with primary aldosteronism . JAMA 2006; 295: 2638-2645.

35.

Fardella CE , Mosso L. , Gomez-Sanchez C. , et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863-1867.

36.

Blumenfeld JD , Sealey JE , Schlussel Y. , et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-885.

37.

Wen CP , Cheng TY , Tsai MK , et al. All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan. Lancet 2008; 371: 2173-2182.

38.

Ribstein J. , Du Cailar G. , Fesler P. and Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16: 1320-1325.

39.

Reincke M. , Rump LC , Quinkler M. , et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 2009; 94: 869-875.

40.

Letavernier E. , Peyrard S. , Amar L. , Zinzindohoue F. , Fiquet B. and Plouin PF Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma . J Hypertens 2008; 26: 1816-1823.

41.

Pizzolo F. , Trabetti E. , Guarini P. , et al. Glucocorticoid remediable aldosteronism (GRA) screening in hypertensive patients from a primary care setting. J Hum Hypertens 2005; 19: 325-327.

42.

Funder JW , Carey RM , Fardella C. , et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 3266-3281.

43.

Young WF Jr. Minireview: primary aldosteronism - changing concepts in diagnosis and treatment. Endocrinology 2003 ; 144: 2208-2213.

44.

Willenberg HS , Kolentini C. , Quinkler M. , et al. The serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio in patients with primary aldosteronism. Eur J Clin Invest 2009 ; 39: 43-50.

45.

Armanini D. and Fiore C. Some considerations about evolution of idiopathic primary aldosteronism. J Endocrinol Invest 2009; 32: 623-625.